^
Association details:
| Biomarker: | KRAS G12 |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | RMC-6236 (RAS inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
652O - Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)
Published date:
10/16/2023
Excerpt:
RMC-6236 exhibits promising anti-tumor activity in patients with KRASG12X PDAC and NSCLC at doses that are well tolerated.
Trial ID:
